| 4 | 1/1 | 返回列表 |
| 查看: 765 | 回復(fù): 3 | |||
zlwcw木蟲 (著名寫手)
|
[交流]
百時美施貴寶公司與清華大學(xué)達成新的戰(zhàn)略合作伙伴關(guān)系 已有3人參與
|
|
Bristol-Myers Squibb has entered into a new multi-year strategic partnership with the Tsinghua University of Beijing. The pharmaceutical company will be funding research efforts at the Chinese university's school of life sciences, focusing on the identification of novel targets in oncology and immunoscience. In addition, the partnership will focus on structural biology research, a process involving mapping the 3D protein structure of biological molecular targets to serve as the basis for future drug discovery projects. This will be the first time that Bristol-Myers Squibb has entered into a China-based discovery collaboration, with the resulting research to benefit patients around the world. Dr Francis Cuss, senior vice-president for research at Bristol-Myers Squibb, said: "We are delighted to be working with Tsinghua University, a world-renowned and highly esteemed research-based academic institution with expertise in target identification and structural biology that will support the discovery of new medicines." Earlier this year, the firm announced a new alliance with the Duke Translational Medicine Institute, which will initially focus on the development of an idiopathic pulmonary fibrosis drug. 2012年5月16日,百時美施貴寶(Bristol-Myers Squibb)公司已與清華大學(xué)達成戰(zhàn)略合作伙伴關(guān)系。 百時美施貴寶公司將資助清華大學(xué)生命科學(xué)學(xué)院的研究工作,重點在于腫瘤學(xué)及免疫學(xué)領(lǐng)域新靶標(biāo)的鑒定。此外,此次合作關(guān)系將重點放在結(jié)構(gòu)生物學(xué)研究。結(jié)構(gòu)生物學(xué)涉及描繪生物分子靶標(biāo)的3D蛋白結(jié)構(gòu),為未來的藥物開發(fā)項目奠定基礎(chǔ)。 這是施貴寶公司首次與我國的科研機構(gòu)達成合作伙伴,該項研究合作的結(jié)果將造福世界各地的患者。 施貴寶公司研發(fā)高級副總裁Francis Cuss博士稱:"我們很高興能與清華大學(xué)展開合作。清華大學(xué)是享譽全球及備受尊敬的專業(yè)學(xué)術(shù)機構(gòu),其在靶標(biāo)識別及結(jié)構(gòu)生物學(xué)方面的專業(yè)知識將有助于新藥物的探索和發(fā)現(xiàn)。" 今年早些時期,施貴寶公司宣布與杜克大學(xué)轉(zhuǎn)化醫(yī)學(xué)研究所達成新的聯(lián)盟,合作最初將專注于特發(fā)性肺纖維化藥物的開發(fā)。(生物谷bioon.com) |
鐵桿木蟲 (著名寫手)

木蟲 (正式寫手)
| 4 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|